Hilterapia®: an ad hoc course in ASAlaser for two Arab physicians

23 March 2012 - Training -

Deepen the application modalities of Hilterapia® for treatment of specific diseases, know "live" the ease of use and the benefits that can be obtained after only a small number of sessions: these are the reasons that led to ASAlaser, on recommendation of the distributor for Saudi Arabia Rehab Al Safwa Est, Dr. Alanazi Malik Hamoud and Dr. Alqahtani Adbulaziz Theeb from Al-Kharj University Hospital (Prince Salman Bin Abdulaziz University).

In Arcugnano the two doctors, with the support Hilterapia® staff , took part in a targeted training course aimed at increasing their expertise with the therapy.

 

You might also be interested in ...

See all articles

M-Hi laser training UK
News - 22/10/2025
From 30 September to 3 October, the tour visited three cities in the United Kingdom, involving physiotherapists and specialists who have chosen the M-Hi and HIRO TT laser systems.
Training ASAlaser devices for Taiwanese customers
News - 10/09/2025
The initiative offered a concrete and inspirational journey, allowing participants to delve deeper into the potential of the patented MLS® and Hilterapia® technologies, with a particular focus on the...
ASA Training Experience
News - 18/06/2025
Two immersive days of advanced clinical training as a privileged meeting point for health professionals interested in learning more about the use of Hilterapia® and MLS® Laser Therapy in therapeutic...
MLS Laser Therapy for TMD
Blog - 22/10/2025
A recent publication from Chulalongkorn University (Thailand) demonstrated how an integrated and conservative approach, supported by MLS® Laser Therapy, can offer highly effective clinical results.
M-Hi laser training UK
News - 22/10/2025
From 30 September to 3 October, the tour visited three cities in the United Kingdom, involving physiotherapists and specialists who have chosen the M-Hi and HIRO TT laser systems.
Press - 07/10/2025
Recent research and pilot studies highlight the benefits of laser therapy in treating radiodermatitis and peripheral neuropathy induced by radiation and chemotherapy for breast cancer.